Nasdaq pgen.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.Precigen, Inc. Common Stock (PGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release second quarter and first half 2021 financial results after the market closes on Monday, …PGEN Pre-Market Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary ...

Jan 24, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

GERMANTOWN, Md., Oct. 9, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that leading science and technology company and existing shareholder Merck KGaA, Darmstadt, Germany, …

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...Quite a few insiders have dramatically grown their holdings in Precigen, Inc. (NASDAQ:PGEN) over the past 12 months. An insider's optimism about the company's prospects is a positive sign. While ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using ...PGENNASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast PGEN chart Today −8.68% 5 days 10.50% 1 month 2.31% 6 months −16.29% Year to date −29.62% 1 year −42.75% 5 years …

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. ...Precigen Inc (NASDAQ:PGEN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...(NASDAQ: PGEN) Precigen currently has 248,919,096 outstanding shares. With Precigen stock trading at $1.16 per share, the total value of Precigen stock (market capitalization) is $288.75M . Precigen stock was originally listed at a price of $24.73 in Aug 8, 2013 .Nov 24, 2023 · Precigen Inc (NASDAQ:PGEN) trade information. After registering a 3.17% upside in the last session, Precigen Inc (PGEN) has traded red over the past five days. The stock hit a weekly high of 1.2700 this Wednesday, 11/22/23, jumping 3.17% in its intraday price action. The 5-day price performance for the stock is 7.55%, and 2.70% over 30 days.

Dec 1, 2023 · Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock. GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offeri... 11 months ago - PRNewsWire. Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.Find the latest Earnings Report Date for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative ...

Nov 24, 2023 · The stock price of Precigen Inc (NASDAQ: PGEN) has jumped by 3.17 compared to previous close of 1.11. Despite this, the company has seen a gain of 7.55% in its stock price over the last five trading days. InvestorPlace reported 2023-11-22 that In this market cycle that we are experiencing, new opportunities arise to take […] Aug 28, 2023 · Precigen ( NASDAQ: PGEN) is a clinical-stage biopharmaceutical firm focusing on next-generation gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases ...

Precigen Inc (NASDAQ:PGEN) is a company dedicated to creating innovative gene and cell therapies to improve the lives of patients.In their latest updates, they have shared financial information ...Aug 22, 2022 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... 11.2%. Market Average Movement. 6.0%. 10% most volatile stocks in US Market. 15.4%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: PGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week. Volatility Over Time: PGEN's weekly volatility (13%) has been stable over the past …Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Precigen (NASDAQ:PGEN) Insider Buying and Selling Activity. Current Insider Ownership Percentage 41.70%. Number Of Insiders Buying (Last 12 Months) 6. Amount Of Insider Buying (Last 12 Months) $21.01 M. Number Of Insiders Selling (Last 12 Months) 5. Amount Of Insider Selling (Last 12 Months) $513,769.48.SIGA Technologies, Inc. (NASDAQ:SIGA), Genmab A/S (NASDAQ:GMAB), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN) are some of the highest growth and profitable ...GERMANTOWN, Md., March 28, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat …Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (NASDAQ:PGEN) priced an offering of ~42.86M common shares at $1.75 apiece to raise about $75M in gross proceeds. The company also granted the underwriters a 30-day option to buy up to an ...

The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

Dec 13, 2021 · Quite a few insiders have dramatically grown their holdings in Precigen, Inc. (NASDAQ:PGEN) over the past 12 months. An insider's optimism about the company's prospects is a positive sign. While ... Precigen (NASDAQ:PGEN), a Virginia-based biopharmaceutical company, focuses on advancing gene and cell therapies to improve patient outcomes for unmet medical needs. The company uses proprietary ...InvestorPlace.com writer Gabriel Osorio-Mazzilli identifies Precigen (NASDAQ:PGEN) as a stock to buy this week following updates about the firm’s flagship PRGN-2012 therapy, an immunotherapy ...Precigen Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of novel gene and cell therapies, has developed a ground-breaking technology that enables the treatment of ...Over the past 30 days, the shares of Precigen Inc (NASDAQ:PGEN) have changed 11.21%. Short interest in the company has seen 16.25 million shares shorted with days to cover at 9.69. Wall Street analysts have a consensus price target for the stock at $9.00, which means that the shares’ value could jump 86.78% from current levels.Nov 20, 2023 · In the last trading session, 2.49 million Precigen Inc (NASDAQ:PGEN) shares changed hands as the company’s beta touched 1.83. With the company’s per share price at $1.18 changed hands at $0.03 or 2.61% during last session, the market valuation stood at $293.73M. PGEN’s last price was a discount, traded about -94.07% off its 52-week high ... Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...The latest price target for . Precigen (NASDAQ: PGEN) was reported by HC Wainwright & Co. on Thursday, August 10, 2023.The analyst firm set a price target for 6.00 expecting PGEN to rise to within ...You may be quick to point out that total product and service revenue registered just $26.3 million in 2014, but the growth of Intrexon's platform is ramping steeply. When asked about the potential ...

InvestorPlace.com writer Gabriel Osorio-Mazzilli identifies Precigen (NASDAQ:PGEN) as a stock to buy this week following updates about the firm’s flagship PRGN-2012 therapy, an immunotherapy ...Dec 1, 2023 · Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock. GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offeri... 11 months ago - PRNewsWire. Find the latest Institutional Holdings data for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.Instagram:https://instagram. ibkr stock pricevanguard windsor ii fund admiralamd stock prediction 2025alibaba stock prediction Precigen Inc (NASDAQ:PGEN) ... Institutional investors purchased a net $3.0 million shares of PGEN during the quarter ended June 2019. This may signal that the ...PGEN : 1.0100 (-7.34%) Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade Zacks - Fri Jan 27, 11:00AM CST. Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. does webull have a simulatorbuy target stock Precigen, Inc. (NASDAQ:PGEN) shares tumbled 26% to $1.63 after the company reported pricing of $75.0 million public offering of common stock. Shares of Grom Social Enterprises, Inc. ... adove stock price (NASDAQ: PGEN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%. What is PGEN's Price Target? According to 2 Wall Street analyst s that have issued a 1 year PGEN price target, the average PGEN price target is $10.00 , with the highest PGEN stock price forecast at $14.00 and the lowest PGEN stock ... (NASDAQ: PGEN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%. What is PGEN's Price Target? According to 2 Wall Street analyst s that have issued a 1 year PGEN price target, the average PGEN price target is $10.00 , with the highest PGEN stock price forecast at $14.00 and the lowest PGEN stock ...